chartexchange

Intellia concludes Phase III ATTRv-PN study enrolment

Clinical Trials Arena | Nov 5, 2026 5:38 AM EST

Intellia Therapeutics has concluded patient enrolment in MAGNITUDE-2, a Phase III clinical study investigating nexiguran ziclumeran, known as nex-z, in adults with hereditary ATTRv-PN.
The post Intellia concludes Phase III ATTRv-PN study enrolment appeared first on Clinical Trials Arena .

Read original article